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Worldwide, hepatocellular carcinoma (HCC) is a common, refractory, malignant tumor. Surgical resection is feasible
in only a few patients, because of limited hepatic reserve and multifocality of tumors at diagnosis. Percutaneous
ablation therapies, including injection of ethanol (PEI) or acetic acid (PAI), radiofrequency ablation (RFA), and microwave
coagulation therapy (MCT), have been the major treatments for unresectable HCC in the past decade. PEI is well
established for small (< 3 cm) HCC, and PAI is equally as effective as PEI, but with fewer treatment sessions.
RFA has recently been suggested to have excellent tumor-ablating ability because it produces a fixed and predictable
tumor necrosis zone. Although RFA is also effective for medium-sized HCC, the overall complication rate may be
higher than previously assumed. MCT is similar to RFA in its clinical application and potential adverse effects.
A combination approach using percutaneous ablation therapy and transcatheter arterial embolization was shown
to be effective for large HCC. Other approaches, such as injection of hot saline or yttrium-90 microspheres, cryoablation,
or interstitial laser photocoagulation, are less often used nowadays. Multimodal, image-guided, tailored therapy,
rather than a fixed treatment algorithm, might be more practical for unresectable HCC. In conclusion, although long-
term survival is possible in selected patients with HCC, the overall prognosis remains suboptimal, especially in
patients with unfavorable tumor characteristics. While newer anti-tumor therapies with improved efficacy are needed,
information about a more rational approach to the use of existing therapeutic options may help to enhance treatment
strategies for HCC. [J Chin Med Assoc 2005;68(4):155–159]
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Introduction
Hepatocellular carcinoma (HCC) is a common malig-
nant neoplasm that principally affects individuals from
Asia and Africa.1 However, recent epidemiologic
surveys suggest that prevalence and mortality rates for
HCC are increasing in North America and Europe.2,3
Several treatments for HCC have been developed dur-
ing the past 2 decades. Surgical resection is generally
believed to be the standard form of curative therapy;
however, it is possible only in a small subgroup of
patients because of the presence of multifocal tumors
or compromised hepatic reserve at diagnosis.4 Liver
transplantation is another treatment option, especially
for patients with advanced cirrhosis, but patients on
the waiting list for transplantation far outnumber
potential cadaveric or living hepatic donors. Among
the various non-surgical interventions, percutaneous
ultrasound-guided therapy, including injection of
ethanol or acetic acid, and thermal ablation using
radiofrequency or microwave energy, are the main-
stays of current clinical practice.5 These therapies
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have the advantages of preserving unaffected liver
parenchyma, and avoiding potential complications
from major liver surgery. Numerous studies have
shown that these methods may prolong survival in
patients with unresectable HCC, and combination
therapy with these various approaches may also
enhance treatment responses.
Percutaneous Ethanol Injection (PEI)
The PEI technique was first initiated by Japanese
researchers in the 1980s, when real-time ultrasound
guidance became possible. Injected pure ethanol
induces local tumor necrosis by protein denaturation,
cell dehydration, and thrombosis of tumor vessels.
HCC is often a hypervascular structure, but is well
encapsulated by a tumor capsule that can limit the
spread of ethanol within the tumor nodule, which is
usually soft in consistency. These features make PEI
one of the most commonly used methods of percu-
taneous ablation therapy.
PEI has the advantages of being safe, relatively
inexpensive, and easy to perform. In addition, PEI
allows the selective treatment of HCC without
damaging adjacent, unaffected liver parenchyma.
Adverse effects are minimal, and include abdominal
pain, fever, and transient elevation of liver enzymes.
Although treatment criteria for PEI may vary from
center to center, most investigators agree that tumor
nodules < 3 cm in size, and no more than 3 nodules,
are the most suitable for PEI.6 Indeed, tumor size is an
important indicator of HCC prognosis in patients
undergoing surgical resection and/or percutaneous
injection therapy.6–8 Small HCC nodules (< 3 cm)
treated with PEI may have a complete response rate
of * 80%, although the response rate may decrease
significantly with increasing size of the nodules.9
Previous, non-randomized studies showed that
patients undergoing PEI had a 3-year survival rate of
47–77%,10–13 although the 2-year tumor recurrence rate
often exceeded 50%.11,12 Such a high recurrence rate
should not be considered a specific defect of percutane-
ous injection therapy. Patients who undergo curative
hepatectomy are also at risk of tumor recurrence after
resection. This is possibly related to unnoticed syn-
chronous tumors, undetected even by highly-sensitive
imaging techniques, at diagnosis.14,15 Retrospective
studies of patients with small HCC indicate that PEI
therapy may be as effective as surgical resection,16,17 but
prospective, randomized trials are required before a
firm conclusion can be made. A recent study also
suggested that PEI may have a role as salvage therapy
in HCC patients who are unlikely to receive arterial
embolization or other non-surgical treatments.18
Percutaneous Acetic Acid Injection (PAI)
Acetic acid 15–50% induces profound tumor necrosis
through a similar mechanism to ethanol.19 It has a
strong ability to penetrate and dissolve lipids and
collagen in tumor septa and capsules, and is
theoretically superior to ethanol in treating HCC
because it frequently induces a persistent state of
complete tumor necrosis.20 Further, a randomized
trial comparing PAI with PEI was conducted in 60
patients with small HCC, and the local 2-year
recurrence rate was considerably less for PAI than
PEI (10% vs 44%).21 However, the efficacy of PEI in
the latter study was much poorer than that reported
by other investigators.9–13 Our recent study of PAI
versus PEI efficacy in HCC showed that recurrence
rates and long-term survival rates were similar between
the 2 groups, and that patients given PAI had fewer
treatment sessions and a shorter hospital stay.22
The efficacy of PAI was compared with that of
transcatheter arterial chemoembolization (TACE)
in HCC patients with tumors of up to 6 cm:23 no
significant difference in progression-free or overall
survival was noted between the 2 treatment groups;
this also applied in a subgroup analysis of patients
with small HCC (< 3 cm). However, in patients
with tumors > 3 cm, TACE tended to produce a bet-
ter long-term outcome than PAI, suggesting a less
satisfactory effect for PAI in large HCC.23
Radiofrequency Ablation (RFA)
RFA has recently become a widely used treatment for
HCC.5 In this procedure, the puncture probe has
an insulated shaft and a non-insulated tip, which is in-
serted into the lesion under ultrasound guidance. The
patient forms part of the electric circuit, with ground-
ing pads on the thighs or back. The radiofrequency
energy emitted from the needle tip induces ionic
agitation and frictional heat. Thus, it is the surround-
ing tissue, rather than the electrode itself, that pro-
duces heat energy to destroy tumor cells. Because
of its excellent necrotizing effect, RFA has become
a highly effective, local ablative therapy for HCC.
A study comparing the efficacy of RFA with that of
PEI in small HCC showed no significant difference
between rates of complete tumor necrosis (90% vs
80%).24 In a recent, randomized trial, 2-year survival
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rates were also not significantly different between
patients undergoing RFA versus PEI (98% vs 88%);
however, patients in the RFA group had a much lower
2-year local recurrence rate than those in the PEI
group (4% vs 38%).25 Another study showed, from ex-
planted livers, that viable tumor was still present in
7 of 12 patients who underwent RFA before liver
transplantation.26 The reason for the therapeutic ad-
vantage of RFA over PEI is that the zone of tumor
necrosis in RFA is generally fixed and predictable,
whereas the effect of PEI is highly dependent on the
diffusion pattern of ethanol in the tumor nodule. A
major advantage of RFA over PAI or PEI is that RFA
can be used to treat medium- or large-sized HCC
() 8 cm in diameter).27,28 For small HCC, RFA was
reported to have efficacy comparable to that of surgical
resection.29 Moreover, RFA is an effective treatment
for post-resection tumor recurrence,30 and can be used
to “bridge” patients to liver transplantation.31
While RFA is generally considered a safe procedure,
a recent study found, from a systematic survey, that the
complication rate for RFA was higher than previously
assumed.32 In addition, different treatment protocols
and electrode types may affect treatment responses
and tumor recurrence rates, and besides its potentially
high complication rate, RFA has other limitations. For
example, when the tumor nodule is close to major
blood vessels, the radiofrequency energy will be car-
ried away by the blood flow (the “heat-sink” effect),
resulting in a suboptimal treatment response. Another
drawback is that if the electrode tip becomes too hot
during ablation, tissue charring may lead to increased
tissue impedance and a smaller thermal-ablated area.
Post-treatment tumor seeding is also a serious concern.
From a Spanish study group, 4 of 32 patients (12.5%)
developed needle-track seeding up to 1.5 years after
RFA.33 Tumors located in subcapsular regions, or with
aggressive behavior, often had neoplastic seeding af-
ter treatment. Although there is increasing evidence
to show that RFA is highly effective, and some inves-
tigators have suggested that RFA may become the
treatment of choice for patients with unresectable
HCC,34 more studies are required to confirm the
overall efficacy of RFA relative to other treatments.
Microwave Coagulation Therapy (MCT)
With a similar thermal-ablation mechanism to RFA,
MCT uses a microwave coagulator that generates and
transmits microwave energy to a needle electrode inserted
in the tumor nodule. MCT has been studied in patients
with HCC, and in those with hepatic metastasis.35–37
It can be used with percutaneous or laparoscopic
methods to destroy tumor nodules, and can also be
used to control tumor bleeding from ruptured HCC,
or to prevent massive blood loss in liver surgery.38
The therapeutic efficacy of MCT was 70% for small
HCC (< 3 cm) and 55% for large HCC (> 3 cm).35
Another report showed that the 9-month, local recur-
rence rate was 2% in patients with small HCC, com-
pared with 8% in large HCC;39 the reported 3-year sur-
vival rate ranged from 73–86%.39–41 Compared with
PEI in patients with moderately or poorly differentiated
HCC, MCT produced better local control and longer
survival.42 MCT is generally safe and well tolerated. Its
limitations and complications are similar to those of
RFA, including abscess or biloma formation, bleeding,
liver failure, and cancer dissemination.35–42
Combination Therapy and Treatment
Algorithm
By using different anti-tumor mechanisms in combi-
nation therapy, treatment responses may be enhanced
and treatment targets might be extended to include
medium (3–5 cm) or large (> 5 cm) HCC. Examples
of combination therapy include TACE + PEI,43,44
TACE + MCT,45 TACE + PAI,46 and RFA after arterial
occlusion.47 Combination therapy frequently induces a
higher rate of complete tumor necrosis than single
interventions. This may have important prognos-
tic significance because an initial complete response
could reduce the risk of tumor dissemination and re-
currence,48 and indeed, there is evidence that tumor
recurrence may induce hepatic decompensation.49
However, it should be noted that the overall complica-
tion rate may also increase in patients undergoing
combination therapy, as the risk of adverse events is
likely to be additive from constituent treatments.
A recent study proposed that multimodal, image-
guided, tailored therapy, rather than a “fixed” treat-
ment algorithm, may be more practical for unresect-
able HCC.50 Nevertheless, although it has not been
completely agreed, RFA may be considered the first-
choice intervention; PEI or PAI is preferred for nodules
at risk from RFA complications; and selective TACE is
preferred for nodules not recognizable at ultrasound
examination, for nodules not re-treatable after an un-
successful ablation technique, and for multiple sat-
ellite nodules. Other percutaneous ablation therapies
that have been reported in the literature include the in-
jection of hot saline or yttrium-90 microspheres,51,52 in-
terstitial laser photocoagulation,53 and cryoablation.54
Although these methods were potentially effective
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in HCC, they are not frequently used nowadays. Ag-
gressive tumor-ablation therapy for HCC patients
with decompensated cirrhosis is not recommended,
because the expected survival in such patients is usually
very limited; moreover, the risk of treatment-induced
liver failure is substantially high, and there appears to
be no solid survival benefit for these patients.
Future Perspectives
The clinical scenarios of HCC at presentation may vary
widely.55 The severity of co-existing cirrhosis is the key
non-tumoral factor limiting survival. The choice of
ablation therapy depends on experience and facilities
at the referral center. Although long-term survival is
possible in selected patients with unresectable HCC,
overall outcomes remain unsatisfactory, especially in
patients with unfavorable prognostic indicators. While
awaiting newer anti-tumor therapies with improved
efficacy, it is clear that the design of a more rational
approach to use of existing treatments may help to
overcome some of the limitations of existing treatments
and improve therapeutic outcomes. Further well-
designed studies are required to resolve the remain-
ing controversial issues regarding the treatment of
patients with unresectable HCC.
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